Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genmab A/S

Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin

At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.

Clinical Trials Research & Development

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Strategy Clinical Trials

Zoll Medical Signs Definite Agreement To Buy Itamar Medical For $538M

The combination of Zoll Medical and Itamar Medical would help strengthen the collaboration between the worlds of cardiology and sleep medicine, Jon Rennert, Zoll’s CEO said.

Digital Health Financing

Coronavirus Update: FDA Approves Pfizer/BioNTech's Comirnaty

The FDA granted an expected, though long-awaited, approval to the COVID-19 vaccine. Also, Korean regulators have begun a review of Russian vaccine CoviVac, while Bavarian Nordic has initiated a Phase II study of its vaccine booster candidate and received a commitment for up to DKK 800m from the Danish government.

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register